Viela Adds Momentum To Burgeoning NMOSD Market With Pivotal Inebilizumab Results

 
• By Jo Shorthouse
  
Bike rider
Viela's N-MOmentum trial results look to add treatment options for neuromyelitis optica patients • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D